Literature DB >> 9746596

Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.

M F Rocha1, A M Soares, C A Flores, T S Steiner, D M Lyerly, R L Guerrant, R A Ribeiro, A A Lima.   

Abstract

Clostridium difficile toxin A is associated with enterocolitis in animals and humans. However, the mechanisms of its secretory and damaging effects are not totally understood. In this work, we examined the intestinal secretion of electrolytes and water caused by supernatants from macrophages stimulated with toxin A in rabbit ileal mucosa mounted in Ussing chambers. We also investigated the mechanism by which the intestinal secretory factor (ISF) is released from stimulated macrophages. Supernatants from macrophages stimulated with toxin A caused potent intestinal secretion (change in short-circuit current [DeltaIsc], 76 microA x cm-2; P < 0.01). The release of the ISF was pertussis toxin sensitive (reduction, 61%; P < 0.01) and was also reduced (P < 0.05) by a protein synthesis inhibitor (67%), protease inhibitors (57%), a phospholipase A2 inhibitor (54%), a cyclo-oxygenase inhibitor (62%), a dual cyclo- and lipoxygenase inhibitor (48%), a platelet-activating factor (PAF) receptor antagonist (55%), and tumor necrosis factor alpha (TNF-alpha) synthesis inhibitors (48%). However, this release was not inhibited by a lipo-oxygenase inhibitor. Monoclonal anti-interleukin 1beta (IL-1beta) but not anti-IL-1alpha antibody blocked (72%; P < 0.01) the secretory action of the ISF, as did recombinant human IL-1 receptor antagonist (80%; P < 0.01). High levels of IL-1beta (3,476 pg/ml) were detected by an enzyme-linked immunosorbent assay in the above supernatants. Furthermore, the addition of IL-1beta to the serosal side caused a potent secretory effect (DeltaIsc, 80 microA x cm-2; P < 0.01). These results show that macrophages stimulated with toxin A release an ISF capable of provoking intestinal secretion. The regulation of this factor is dependent upon the activation of the G protein. In addition, prostaglandins, PAF, and TNF-alpha are involved in the release of the ISF. We conclude that IL-1beta is probably the ISF released by macrophages in response to toxin A.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746596      PMCID: PMC108607     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Effect of sulfidopeptide leukotrienes D4 and E4 on ileal ion transport in vitro in the rat and rabbit.

Authors:  P L Smith; D P Montzka; G P McCafferty; M A Wasserman; J D Fondacaro
Journal:  Am J Physiol       Date:  1988-08

2.  Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peritoneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes.

Authors:  M F Rocha; M E Maia; L R Bezerra; D M Lyerly; R L Guerrant; R A Ribeiro; A A Lima
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 3.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

4.  Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon.

Authors:  T J Mitchell; J M Ketley; S C Haslam; J Stephen; D W Burdon; D C Candy; R Daniel
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

Review 5.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

6.  Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro.

Authors:  A A Lima; D M Lyerly; T D Wilkins; D J Innes; R L Guerrant
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

7.  Purification and characterization of toxins A and B of Clostridium difficile.

Authors:  N M Sullivan; S Pellett; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

8.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha.

Authors:  F Bussolino; G Camussi; C Baglioni
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

9.  Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021.

Authors:  M Rola-Pleszczynski; B Pignol; C Pouliot; P Braquet
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

10.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

View more
  4 in total

Review 1.  Clostridium difficile toxins: mechanism of action and role in disease.

Authors:  Daniel E Voth; Jimmy D Ballard
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

2.  Clostridium difficile toxin B differentially affects GPCR-stimulated Ca2+ responses in macrophages: independent roles for Rho and PLA2.

Authors:  Robert A Rebres; Christina Moon; Dianne Decamp; Keng-Mean Lin; Iain D Fraser; Stephen B Milne; Tamara I A Roach; H Alex Brown; William E Seaman
Journal:  J Leukoc Biol       Date:  2010-03-03       Impact factor: 4.962

Review 3.  The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.

Authors:  Xingmin Sun; Simon A Hirota
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

4.  Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea.

Authors:  Hanna Pituch; Alex Van Belkum; Nicole Van Den Braak; Piotr Obuch-Woszczatynski; Henri Verbrugh; Felicja Meisel-Mikołajczyk; Mirosław uczak
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.